MYUNGMOON PHARM Files 2025 Corporate Governance Report... Turns Profitable but Fails Key Governance Indicators, No Dividend
For FY2025, consolidated revenue reached 195.2B KRW (up from 186.4B), operating profit 6.8B KRW (up from 1.9B), and net profit turned positive at 1.4B KRW. However, no dividend was declared due to insufficient distributable reserves.
Failed to comply with 12 out of 15 key governance indicators, including no 4-week prior notice for shareholder meetings, no dividend predictability, lack of CEO succession and internal control policies, board chair not an independent director, no cumulative voting, and no accounting/finance expert on internal audit.
Board consists of 1 inside and 2 outside directors (all male). No board committees. CEO and chairperson roles not separated.
Single full-time auditor. External auditor (Samil PwC) appointed by regulatory authority. Internal audit support lacks independence.
Shareholder proposals (dismissal of CEO and disposal of subsidiary) were rejected by the board. No public letters from institutional investors.
Company plans to improve dividend policy, establish board operation rules, introduce outside director evaluation, and strengthen internal controls.
[AI Comprehensive Analysis]This disclosure is neither a positive nor negative catalyst for enterprise value, but the multiple governance deficiencies present investment risks. Despite a turnaround to profitability, the absence of dividends weakens shareholder return expectations. Medium- to long-term stock performance will hinge on the implementation of promised governance improvements.